Thursday, March 1, 2001
The researchers reported in scientific exhibit 4 that they enrolled 255 patients who were randomized into one of two treatment groups-appropriate care with and without hylan G-F 20. Costs related to the patient's osteoarthritis in the knee and other joints were collected from the societal viewpoint. Effectiveness was measured using WOMAC, SF-36 and Health Utilities Index Mark 3.
The group receiving hylan G-F 20 was clinically and statistically superior for all primary and secondary effectiveness measures, said Nicholas Bellamy, MD, University of Queensland, Queensland, Australia, and colleagues. The mean annual incremental cost per patient was $710 for the group treated with hylan G-F 20. The largest contributor ($675) to the cost difference was the price of hylan G-F 20. The second largest contributor ($-280) was the savings in other costs of treating the knee osteoarthritis, primarily medications and other therapies.
Over the year, appropriate care with the hylan G-F 20 had a statistically significant gain of 0.071 quality-adjusted years (QALY) which resulted in a societal cost of $10,000 Canadian per QALY gained. The researchers concluded that the results provide strong evidence for adoption of treatment with hylan G-F 20 in patients with knee osteoarthritis.
In addition to Dr. Bellamy, the researchers were George Torrance, PhD, Burlington, Ontario; Valery Walker, MSc, Burlington, Ontario; Jean Pierre Raynauld, MD, Institut de Rheumatologie de Montreal, Montreal, Quebec; Charlie Goldsmith, PhD, St. Joseph's Hospital, Hamilton, Ontario; Peter Tugwell, MD, Ottawa General Hospital, Ottawa, Ontario; Margarita Schultz, MBA, Pharmaccess, Inc., Westmont, Quebec; Robert Bourne, MD, London Health Sciences Centre, London, Ontario; K. Wayne Marshall, MD, Toronto Hospital Western Division; and Phil Brand, PhD, Biomatrix, Ridgeland, NJ. Biomatrix, Inc., Ridgeland, N.J., provided funding for the study
|2001 Academy News March 1 Index C|
Last modified 14/February/2001 by IS